Lianne M Haveman1, Roelof van Ewijk1, Elvira C van Dalen1, Willemijn B Breunis2,3, Leontien Cm Kremer1,2, Henk van den Berg2, Uta Dirksen4, Johannes Hm Merks1,2. 1. Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands. 2. Department of Paediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. 3. Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. 4. Pediatrics III, Sarcoma Centre, West German Cancer Centre, University Hospital Essen, Essen, Germany.
Abstract
BACKGROUND: Ewing sarcoma is a solid tumour, which is the second most common primary bone malignancy in children, often occurring in the long bones and pelvis. An incidence rate of 4.5 per million a year is reported, with a peak incidence of 11 per million at the age of 12 years. Despite more intensive chemotherapy, 30% to 40% of young people with Ewing sarcoma will have recurrence of the disease. Less than 30% of young people with a recurrence of Ewing sarcoma are alive at 24 months, and less than 10% are alive at 48 months. High-dose chemotherapy (HDC), followed by autologous haematopoietic cell transplantation (AHCT), is used in a variety of paediatric groups with diverse solid tumours. The hypothesis is that HDC regimens may overcome resistance to standard polychemotherapy, and this way may eradicate minimal residual disease, leading to improved survival after a first recurrence of disease. OBJECTIVES: To assess the efficacy of HDC with AHCT versus conventional chemotherapy in improving event-free survival, overall survival, quality-adjusted survival, and progression-free survival in children, adolescents, and young adults with first recurrence of Ewing sarcoma, and to determine the toxicity of the treatment. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, conference proceedings from the SIOP, ASPHO, CTOS, ASBMT, EBMT, and EMSOS, and two trial registries in January 2020. We also searched reference lists of relevant articles and review articles. SELECTION CRITERIA: We planned to include randomised controlled trials (RCTs) or (historical) controlled clinical trials (CCTs) comparing the effectiveness of HDC plus AHCT with conventional chemotherapy for children, adolescents, and young adults (up to 30 years old at the date of diagnostic biopsy) with a first recurrence of Ewing sarcoma. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We did not identify any eligible studies. AUTHORS' CONCLUSIONS: Since we did not identify any eligible studies, we are unable to draw any conclusions about the efficacy and toxicity of HDC with AHCT versus conventional chemotherapy in children, adolescents, and young adults with a first recurrence of Ewing sarcoma. Further high-quality research is urgently needed.
BACKGROUND: Ewing sarcoma is a solid tumour, which is the second most common primary bone malignancy in children, often occurring in the long bones and pelvis. An incidence rate of 4.5 per million a year is reported, with a peak incidence of 11 per million at the age of 12 years. Despite more intensive chemotherapy, 30% to 40% of young people with Ewing sarcoma will have recurrence of the disease. Less than 30% of young people with a recurrence of Ewing sarcoma are alive at 24 months, and less than 10% are alive at 48 months. High-dose chemotherapy (HDC), followed by autologous haematopoietic cell transplantation (AHCT), is used in a variety of paediatric groups with diverse solid tumours. The hypothesis is that HDC regimens may overcome resistance to standard polychemotherapy, and this way may eradicate minimal residual disease, leading to improved survival after a first recurrence of disease. OBJECTIVES: To assess the efficacy of HDC with AHCT versus conventional chemotherapy in improving event-free survival, overall survival, quality-adjusted survival, and progression-free survival in children, adolescents, and young adults with first recurrence of Ewing sarcoma, and to determine the toxicity of the treatment. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, conference proceedings from the SIOP, ASPHO, CTOS, ASBMT, EBMT, and EMSOS, and two trial registries in January 2020. We also searched reference lists of relevant articles and review articles. SELECTION CRITERIA: We planned to include randomised controlled trials (RCTs) or (historical) controlled clinical trials (CCTs) comparing the effectiveness of HDC plus AHCT with conventional chemotherapy for children, adolescents, and young adults (up to 30 years old at the date of diagnostic biopsy) with a first recurrence of Ewing sarcoma. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We did not identify any eligible studies. AUTHORS' CONCLUSIONS: Since we did not identify any eligible studies, we are unable to draw any conclusions about the efficacy and toxicity of HDC with AHCT versus conventional chemotherapy in children, adolescents, and young adults with a first recurrence of Ewing sarcoma. Further high-quality research is urgently needed.
Authors: Miguel A Diaz; Alvaro Lassaletta; Antonio Perez; Julian Sevilla; Luis Madero; Marta Gonzalez-Vicent Journal: Pediatr Hematol Oncol Date: 2010-05 Impact factor: 1.969
Authors: Lianne M Haveman; Roelof van Ewijk; Elvira C van Dalen; Willemijn B Breunis; Leontien Cm Kremer; Henk van den Berg; Uta Dirksen; Johannes Hm Merks Journal: Cochrane Database Syst Rev Date: 2021-09-02
Authors: G Bacci; A Toni; M Avella; M Manfrini; A Sudanese; D Ciaroni; S Boriani; E Emiliani; M Campanacci Journal: Cancer Date: 1989-04-15 Impact factor: 6.860
Authors: Carlos Rodríguez-Galindo; Tiebin Liu; Matthew J Krasin; Jianrong Wu; Catherine A Billups; Najat C Daw; Sheri L Spunt; Bhaskar N Rao; Victor M Santana; Fariba Navid Journal: Cancer Date: 2007-07-15 Impact factor: 6.860
Authors: Jeremy Whelan; Marie-Cecile Le Deley; Uta Dirksen; Gwénaël Le Teuff; Bernadette Brennan; Nathalie Gaspar; Douglas S Hawkins; Susanne Amler; Sebastian Bauer; Stefan Bielack; Jean-Yves Blay; Stefan Burdach; Marie-Pierre Castex; Dagmar Dilloo; Angelika Eggert; Hans Gelderblom; Jean-Claude Gentet; Wolfgang Hartmann; Wolf-Achim Hassenpflug; Lars Hjorth; Marta Jimenez; Thomas Klingebiel; Udo Kontny; Jarmila Kruseova; Ruth Ladenstein; Valerie Laurence; Cyril Lervat; Perrine Marec-Berard; Sandrine Marreaud; Jean Michon; Bruce Morland; Michael Paulussen; Andreas Ranft; Peter Reichardt; Hendrik van den Berg; Keith Wheatley; Ian Judson; Ian Lewis; Alan Craft; Heribert Juergens; Odile Oberlin Journal: J Clin Oncol Date: 2018-09-06 Impact factor: 44.544
Authors: Lianne M Haveman; Roelof van Ewijk; Elvira C van Dalen; Willemijn B Breunis; Leontien Cm Kremer; Henk van den Berg; Uta Dirksen; Johannes Hm Merks Journal: Cochrane Database Syst Rev Date: 2021-09-02